Aurasız Ve Görsel Auralı Migren Olgularında Serum Magnezyum Düzeyi Değişikliği

Year 2007, Volume: 24 Issue: 4, 113 - 120, 29.12.2009

Ö.f. Akkaya G. Tunalı

Abstract

Bu çalışmanın amacı, auralı ve aurasız migren gruplarında baş ağrılı ve baş ağrısız dönemde serum magnezyum düzeylerindeki değişiklikleri araştırmaktır.
Çalışmaya, yaşları 17-45 arasında değişen, Uluslararası Baş Ağrısı Derneği'nin (International Headache Society (IHS-2004)) kriterlerine göre tanı konulmuş, 25 aurasız, 25 görsel auralı migrenli olgu grupları ile yaş ve cinsiyet dağılımları olgu grupları ile uyumlu 25 sağlıklı bireyden oluşan kontrol grubu alındı. Olgu gruplarına baş ağrılı ve baş ağrısız dönemlerde serum magnezyum düzeyleri ölçüldü. Sonuçlar kontrol grubunun değerleriyle karşılaştırıldı. Auralı ve aurasız migren gruplarında birbirleriyle çelişen veriler elde ettik. Auralı migrenli-lerde, serum magnezyum değerleri, baş ağrılı dönemde hem baş ağrısız döneme hem de kontrol grubuna göre düşük bulundu. Aurasız migren grubunda ise serum magnezyum düzeyleri, baş ağrılı dönemde hem ağrısız dönem ve hem de kontrol grubu ile karşılaştırıldığında değerler arasında anlamlı fark bulunmadı.


Serum Magnesium Levels in Migraine with Visuel Aura and Without Aura Cases
The purpose of this study is to investigate the changes in serum magnesium levels in migraine with aura and without aura patients in both headache periods and headache free periods.
In this study, 25 patients suffering from migraine without aura, 25 patients suffering from migraine with visual aura the ages of whom range from 17 to 45 and of who have been diagnosed according to criteria of the International Headache Society (IHS-2004) and 25 healty people in the control group with the same age and sex as the pilot group have been included. Serum magnesium levels in migraine groups have been examined in both headache and headache free periods. The results have been compared with those of the contro 1 group.
Some contradictory results have been detected in migraine groups with aura and without aura. The serum magnesium levels of migraine with aura group in headache period have been found lower than the levels in headache free period and those of the control group.On the other hand, magnesium levels in migraine group without aura in headache period and headache free period may be said to be insignifantly different when compared with those of the control group.

Keywords

-

References

• Hayran O, Zarifoglu M, Siva A. Bafl ağrısı Epidemiyolojisi. Erdine S (Ed.) Ağrı. 2000: 181–183.
• Silberstein SD, Lipton RB,Goodsby PJ.(Ed) Headache in Clinical Practise: Isıs Medical Media pres 1998: 1–7, 41–58, 61–89.
• Siva A, Saip S. Migren: Klinik özellikler. Erdine S(Ed.) Ağrı 2000: 192–198.
• Bolay H, Dalkara T. Birincil bafl ağrılarının fizyopa- tolojisi. Türkiye Klinikleri Neuroloji Dergisi. 2003; 2: 98–102.
• Leao APP: Spreading depression of activity in the cerebral cortex. Journal of Neurophysiology 1944; 7: 259.
• Egillius L, Splerings H. Pathogenesis of the migraine attack. The Clinical Journal of Pain 2003; 19: 253–262. 7. Eriksen MK, Thomsen LL, Russel MB. Prognosis of migraine with aura. Cephalgia 2004; 24: 18–22.
• Queiraz LP, Rapoport AM, Randell EW. Characteristcs of migraine visual aura. Headache 1997; 37: 137–141.
• Gallai V, Sarchielli P, Coata G, et al. Serum and salivary magnesium levels in migraine. Results in a group of juvenile patients. Headache 1992; 32: 132–135.
• Gallai V, Sarchielli P, Morucci P, et al. Magnesium content of mononuclear blood cells in migraine patients. Headache 1994; 34: 160–165
• Lodi R, Iotti S, Cortelli P, et al. Deficient energy metabolism is associated with low free magnesium in the brains of patients with migraine and cluster headache.Brain Research Bulletin 2001; 54: 437–441.
• Mauskop A. Evidence linking magnesium deficiency to migraineurs. Cephalgia 1999; 19: 766–767.
• Mauskop A, Altura B, Cracco RQ, et al. Deficiency serum ionized magnesium but not total magnesium in patients with migraines. Possible role of ionized calcium/ ionized magnesium ratio. Headache 1993; 33: 135–138.
• Mauskop A, Altura B, Burton M, et al. Serum ionized magnesium levels and serum ionized calsium/ionized magnesium ratios in woman with menstruel migraine. Headache 2002; 42: 242–248.
• Bigal ME, Bordini CA, Teper SJ, et al. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalgia 2002; 22: 345–353.
• Demirkaya fi, Vural O, Dora B, et al. Efficacy of i n t r a v e n o u s magnesium sulphate in the treatment of acute migraine attacks. Headache 2001; 41: 171–177. 17. Faccihinetti F, Sances G, Borella P, et al. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache 1991; 31: 298–301. 18. Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium and feverfew for migraine prophylaxis: a randomized trial. Headache 2004; 44: 885–890.
• Mauskop A, Altura B, Cracco RQ, et al. Intravenous magnesium sulphate rapidly alleviates headaches of various types. Headache 1996; 36: 154–160.
• Peikert A, Willimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: result from a prospective, multicenter, placebo-controlled and d o uble-blind randomized study. Cephalgia 1996; 16: 257–263.
• Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the prophylaxis of migraine -a double-blind p l a c ebo-controlled study. Cephalgia 1996; 16: 436–440. 22. Todd D, Rozen. Aborting a prolonged migraneus aura with intravenous prochlorperosine and magnesium sulphate. Headache 2003; 43: 901–903.
• Wang F, Van Den Eeden SK, Ackerson LM, et al. Oral magnesium oxide prophilaxis of frequent migrainous headache in children: randomized, double-blind, placebo-controlled trial. Headache 2003; 43: 601–610. 24. Headache Classification Subcommitee of the International Headache Society: The International Classification of Headache Disorders. 2. Edition. Cephalgia 2004; 24 Supplement 1.
• Ramadan NM, Halvorson H, Vande-Linde A, et al. Low brain magnesium in migraine. Headache 1989; 29 590–593.
• Boska MD, Welch KM, Barker PB, et al. Contrasts in cortical magnesium, phospholipid and energy metabolism between migraine syndromes. Neurology 2002; 58: 1227–1233
• Trauninger A, Pfund Z, Koszeegi T, et al. Oral magne- sium load test in patient with miqraine. Headache 2002; 42: 114–119.
• Cete Y, Dora B, Ertan C, et al. A randomized p r o s p e c t i v e placebo –controlled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attack in the emergency department. Cephalgia 2005; 25: 199–204.
• Ertafl M: Migren tedavisi. Türkiye Klinikleri Nöroloji Dergisi 2003: 116–123.